Stay updated on INCB001158 Combo with SC Daratumumab vs Daratumumab SC Clinical Trial
Sign up to get notified when there's something new on the INCB001158 Combo with SC Daratumumab vs Daratumumab SC Clinical Trial page.

Latest updates to the INCB001158 Combo with SC Daratumumab vs Daratumumab SC Clinical Trial page
- Check2 days agoChange DetectedAdded EudraCT Number 2018-004076-35 to the study's identifiers and introduced an 'Last Update Posted (Estimated)' timestamp; removed the older 'Last Update Posted' label and the '2023-02' date.SummaryDifference0.3%

- Check9 days agoChange DetectedThe screenshots depict the same study details page with no changes to the main sections (Overview, Eligibility, and Outcomes). Any differences seem to be formatting or minor text edits.SummaryDifference0.4%

- Check16 days agoNo Change Detected
- Check38 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference2%

- Check45 days agoChange DetectedCore disease name updated from 'Plasma cell myeloma' to 'Multiple myeloma' and software version advanced from v3.0.2 to v3.1.0.SummaryDifference0.1%

- Check59 days agoChange DetectedUpdated revision from v3.0.1 to v3.0.2; 'Back to Top' was removed. No changes to core content, pricing, stock, or time-slot availability.SummaryDifference0.1%

- Check66 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.1%

Stay in the know with updates to INCB001158 Combo with SC Daratumumab vs Daratumumab SC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INCB001158 Combo with SC Daratumumab vs Daratumumab SC Clinical Trial page.